Clinical Trials
19 trialsNCT07422805 2026-05-27
ctDNA
Institute of Oncology Ljubljana
Phase 1/2 Active not recruiting
NCT03598998 2026-05-26
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT07302347 2026-05-26
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07070232 2026-05-22
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
Phase 1/2 Recruiting
NCT06305247 2026-05-20
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Active not recruiting
NCT06814496 2026-05-20
RABBIT
University of Arizona
Phase 1/2 Recruiting
NCT02332668 2026-05-18
MK-3475-051
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT05379985 2026-05-15
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT07339176 2026-05-14
OP-NEU-101
Onchilles Pharma Inc
Phase 1/2 Recruiting
NCT01989585 2026-05-13
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03686124 2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
NCT05896839 2026-05-13
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07287917 2026-05-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04464759 2026-05-11
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT05661955 2026-05-11
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT04083599 2026-05-06
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04851119 2026-05-05
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT07281924 2026-05-05
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
University of Wisconsin, Madison
Phase 1/2 Recruiting